Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective

References

• National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation, 2002
   Google Scholar
• Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995;17(5 Suppl.):S505-11
   PubMed Web of Science ®Google Scholar
• Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103:S12-19
   PubMed Web of Science ®Google Scholar
• Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5
   PubMed Web of Science ®Google Scholar
• Boonen S, Autier P, Barette M, et al. Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int 2004;15:87-94
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Fast Facts. Available at http//www.nof.org/osteoporosis/diseasefacts.htm [Last accessed 6 Feb 2008]
   Google Scholar
• Center JR, Nguyen TV, Schneider D, et al. Mortality of all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States 2005–2025. J Bone Miner Res 2007;22:465-75
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-35
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Watts NB, Worley K, Solis A, et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 2004;10:142-51
   PubMedGoogle Scholar
• Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18:25-34
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383-91
   PubMed Web of Science ®Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
   PubMed Web of Science ®Google Scholar
• van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006;22:1757-64
   PubMed Web of Science ®Google Scholar
• Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17:914-21
   PubMed Web of Science ®Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
   PubMed Web of Science ®Google Scholar
• Zethraeus N, Borgström F, Ström O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis – a review of the literature and a reference model. Osteoporos Int 2007;18:9-23
   PubMed Web of Science ®Google Scholar
• Grima DT, Burge RT, Becker DL, et al. Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. Pharm Therapeut 2002;27:448-55
   Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6:217-27
   PubMed Web of Science ®Google Scholar
• Brixner D. Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting. Am J Manag Care 2006;12(7 Suppl.):S191-8
   PubMedGoogle Scholar
• Grima DT, Papaioannou A, Thompson MF, et al. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int 2008;19:687-97
   PubMed Web of Science ®Google Scholar
• Brecht JG, Kruse HP, Möhrke W, et al. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 2004;24:1-10
   PubMedGoogle Scholar
• Jansen JP, Gaugris S, Bergman G, et al. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment of and prevention of osteoporosis in the United Kingdom and the Netherlands. Curr Med Res Opin 2008;00:671-84
   Google Scholar
• Cadarette SM, Katz JN, Brookhart MA, et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 2008;148:637-46
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, Graham CN, Ettinger B, et al. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequent administered oral bisphosphonates. Curr Med Res Opin 2007;23:2517-29
   PubMed Web of Science ®Google Scholar
• Grima D, Pasquale M, Lange J, et al. Cost-effectiveness of risedronate vs. ibandronate: impact of persistence. Presented at the 28th Annual Meeting of the American Society for Bone and Mineral Research, September 14–19, 2006, Philadelphia, PA, USA. Abstract SA351
   Google Scholar
• Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008;19:1039-45
   PubMed Web of Science ®Google Scholar
• Tosteson ANA, Pasquale MK, Lange JL. The impact of persistency patterns on the economic value of osteoporosis treatment. Presented at the 28th Annual Meeting of the American Society for Bone and Mineral Research, September 14–19, 2006, Philadelphia, PA, USA. Abstract SU337
   Google Scholar
• Kelton CML, Pasquale MK. The relative contributions of nonvertebral efficacy, vertebral efficacy, and persistence in determining cost-effectiveness: the case of osteoporosis and implications for payers. Data on file
   Google Scholar